Brain Imaging and Neuroimaging Market Size, Share, and Industry Analysis By Device (Magnetic Resonance Imaging (MRI) [Less than 1.5T, 1.5T, and More than 1.5T], Positron Emission Tomography (PET), Electroencephalography (EEG), Computed Tomography (CT) [High Slice, Mid Slice, Low Slice, and Cone Beam Computed Tomography], and Others), Product Type (Fixed and Portable), By Application (Brain Tumors, Multiple Sclerosis, Dementia, and Others), By End User (Hospitals, Specialty Clinics, Diagnostic Centers, and Others), and Regional Forecast, 2025-2032

The global brain imaging and neuroimaging market is witnessing significant growth owing to the increasing prevalence of neurological disorders such as epilepsy, dementia, and others, resulting in a growing number of scans among the patient population. The surging prevalence and the growing demand for advanced imaging modalities is likely to support the growth of the market globally. Brain imaging and neuroimaging refer to the imaging modalities that help in the diagnosis of neurological disorders among the patient population.

• According to 2024 statistics published by the World Health Organization (WHO), it was reported that about 55.0 million people have dementia globally, over 60% of whom live in low and middle-income countries.

Brain Imaging and Neuroimaging Market Driver

Increasing Prevalence of Neurological Disorders to Drive Market Growth

The increasing prevalence of neurological disorders such as traumatic brain injury, dementia, and others is resulting in a growing number of imaging scans among the patient population. The increasing number of scans, along with a growing number of key players focusing on R&D activities to launch imaging equipment, is expected to support the growth of the market.

• According to the 2024 statistics published by the Collective Minds Radiology, it was reported that approximately 100-150 million magnetic resonance imaging scans are performed worldwide annually.

Download Free sample to learn more about this report.

According to 2023 data published by the National Center for Biotechnology Information (NCBI), it was reported that the prevalence of mild cognitive impairment was 12.3 million in the U.S., 1.4 million in Canada, 6.9 million in Japan, and 3.1 million in Italy.

Brain Imaging and Neuroimaging Market Restraint

Limited Imaging Scans in Emerging Countries May Hinder Market Growth

There is a growing demand for technologically advanced brain imaging and neuroimaging machines, such as magnetic resonance imaging, computed tomography, and others. However, limited awareness about the benefits of early diagnosis, coupled with limited healthcare facilities in emerging countries such as Brazil, China, and others, is resulting in a reduced number of imaging scans, further hampering the growth of the market.

• According to 2023 statistics published by the International Trade Administration (ITA), there are about 7,191 hospitals in Brazil.

Brain Imaging and Neuroimaging Market Opportunity

Demand for Novel Neuroimaging Systems to Foster Future Market Growth

There is an increasing demand for novel imaging machines such as computed tomography, magnetic resonance imaging scans, and others, resulting in the rising focus of key players toward R&D initiatives to launch technologically advanced imaging machines. This is further expected to support the growth of the market. 

• In October 2024, researchers from San Francisco developed a machine learning algorithm to enhance 3T MRIs by synthesizing 7T-like images. Their model enhanced pathological tissue with more fidelity for clinical insights and represents a new step toward evaluating clinical applications of synthetic 7T MRI models.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Disorders, By Key Countries, 2023
• New Product Launches, By Key Players
• Overview: Technological Advancements in Imaging Devices
• Key Industry Developments (Mergers, Acquisitions, Partnerships)
• Impact of COVID-19 on the Market

Analysis by Device

Based on device, the brain imaging and neuroimaging market is divided into magnetic resonance imaging (MRI) [less than 1.5T, 1.5T, and more than 1.5T], positron emission tomography (PET), electroencephalography (EEG), computed tomography (CT) [high slice, mid slice, low slice, and cone beam computed tomography], and others.

The magnetic resonance imaging segment held a prominent market share in 2023. The increasing focus of prominent players toward receiving approvals for technologically advanced MRI scanners is likely to support the segmental growth.

• In November 2024, GE Healthcare received U.S. FDA approval for SIGNA MAGNUS, a high-performance head-only MRI scanner with an aim to expand the field of neuroscience globally.

Analysis by Product Type

Amongst product type, the brain imaging and neuroimaging market is fragmented into fixed and portable.

The fixed segment accounted for a substantial market share in 2023. The segmental growth is due to the growing demand for fixed scanners, further driving the focus of major players toward strategic initiatives to introduce advanced fixed scanners such as PET/CT scanners and others.

• In July 2024, Positrigo, a Swiss-based company, received FDA approval for its PET system NeuroLF with an aim to help diagnose and monitor brain-related disorders such as Alzheimer’s disease, brain tumors, epilepsy, Parkinson’s disease, and others.

Analysis by Application

On the basis of application, the market is divided into brain tumors, multiple sclerosis, dementia, and others.

The brain tumor segment accounted for a significant market share in 2023. The growth is due to the growing prevalence of brain tumors among the patient population, resulting in a rising number of imaging scans globally. This, along with a growing number of product launches for these imaging modalities, is likely to support the segment growth.

• According to 2024 data published by the National Brain Tumor Society, it was reported that approximately 1 million Americans are suffering from primary brain tumors in the U.S.

Analysis by End User

Amongst end user, the brain imaging and neuroimaging market is fragmented into hospitals, specialty clinics, diagnostic centers, and others.

The hospitals segment accounted for a robust market share in 2023. The increasing number of hospitals in developed countries, the growing number of patient visits to the hospitals, and others, are some of the major factors contributing to the growing number of scans and increasing installed bases of imaging systems globally.

• According to 2023 statistics published by the American Health Association (AHA), there are about 6,120 hospitals in the U.S.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for the largest share of the global brain imaging and neuroimaging market in 2023. The growth is owing to several factors, including the growing prevalence of neurological disorders, the growing number of imaging scans, developed healthcare infrastructure, and increasing number of product launches, among others.

• According to 2024 statistics published by the Collective Minds Radiology, approximately 40 million magnetic resonance imaging scans are performed each year in the U.S.

Additionally, Europe is the second-largest market for brain imaging and neuroimaging. The rising geriatric population is resulting in the growing prevalence of neurological conditions, which is further contributing to the demand for advanced imaging equipment in the market. This, along with the increasing focus of key players toward acquisitions and mergers, among others, is further expected to support the regional market growth.

• According to 2024 statistics published by the British Epilepsy Association, one in every four people newly diagnosed with epilepsy is over the age of 65 in the U.K.

The Asia Pacific is expected to grow at a considerable CAGR during the forecast period. The growth is due to the increasing number of key players operating in the market offering advanced imaging machines.

Key Players Covered

The global brain imaging and neuroimaging market is fragmented, with many players.

The report includes the profiles of the following key players:

• GE Healthcare (U.S.)
• Siemens Healthineers (Germany)
• Canon Medical Systems Ltd. (Japan)
• Hitachi, Ltd. (Japan)
• Koninklijke Philips N.V. (Netherlands)
• Varian Medical Systems, Inc. (U.S.)
• Esaote SPA (Italy)

Key Industry Developments

• In February 2024, Koninklijke Philips N.V. collaborated with Synthetic MR, a magnetic resonance imaging (MRI) software solutions company, with an aim to deliver breakthrough artificial intelligence quantitative brain imaging in MR to advance neurology care for patients at the European Society of Radiology.
• In November 2023, Canon Medical Systems Ltd., launched two new AI-enhanced CT solutions at the Radiological Society of North America, the Aquilion ONE / INSIGHT Edition and the Aquilion Serve SP, with an aim to support the growing demand among patients suffering from neurological disorders.